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9 Abstract In Parkinson’s disease (PD), destruction of
10 noradrenergic neurons in the locus coeruleus (LC) may
11 precede damage to nigral cells and subsequently exagger-
12 ate dopaminergic cell loss. We examine if destruction of
13 the locus coeruleus with N-(2-chloroethyl)-N-ethyl-2-bro-
14 mobenzylamine (DSP-4) alters dopaminergic cell loss in
15 substantia nigra (SN) initiated by lipopolysaccharide (LPS)
16 in the rat through an effect on glial cell activation. In rats, a
17 single intraperitoneal dose of DSP-4 administered 8 days
18 previously, caused a marked loss of tyrosine hydroxylase
19 positive neurons in LC but no change in dopaminergic cell
20 number in SN. Unilateral nigral LPS administration
21 resulted in marked dopaminergic cell death with reactive
22 microgliosis associated with enhanced p47phox in OX-6 and
23 OX-42 positive microglia. There was proliferation of
24 inducible nitric oxide synthase (iNOS)-positive cells, for-
25 mation of 3-nitrotyrosine (3-NT) and proliferation of
26 astrocytes that expressed glial cell line-derived neurotro-
27 phic factor (GDNF). Following combined DSP-4 treatment
28 and subsequent administration of LPS, unexpectedly, no
29 further loss of tyrosine hydroxylase (TH)-immunoreactiv-
30 ity (-ir) occurred in the SN compared to the effects of LPS
31 alone. However, there was a marked alteration in the
32 morphology of microglial cell and a reduction of 3-NT-
33 and iNOS-ir was evident. Expression of p47phox was
34 downregulated in microglia but up-regulated in TH-ir
35neurons. No further change in GFAP-ir was observed
36compared to that produced by DSP-4 alone or LPS alone,
37but the expression of GDNF was markedly reduced. This
38study suggests that in contrast to previous reports, prior LC
39damage does not influence subsequent nigral dopaminergic
40cell degeneration induced by LPS. Rather it appears to
41attenuate the microglial response thought to contribute to
42disease progression in PD. 3
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49Introduction
50Noradrenergic neurons arising from the locus coeruleus
51(LC) degenerate with Lewy body pathology in Parkinson’s
52disease (PD) leading to a decrease in mid- and fore-brain
53noradrenaline content (German et al. 1992; Forno et al. 1993;
54del Tredici et al. 2002; Braak et al. 2003). Noradrenergic
55fibres activate a-adrenergic receptors located on dopami-
56nergic neurons in substantia nigra (SN) and stimulation of the
57LC facilitates their burst firing (Grenhoff et al. 1993).
58However, the degeneration of LC noradrenergic neurons in
59PD may precede the loss of dopaminergic cells in SN and it
60has been suggested that LC loss influences the rate of SN loss
61(del Tredici and Braak 2013). For example, in non-human
62primates and mice damage to the nigrostriatal pathway
63induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
64(MPTP) was potentiated by prior destruction of the locus
65coeruleus using the selective noradrenergic neurone toxin,
66N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4)
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67 (Mavridis et al. 1991; Fornai et al. 1996). In reverse, phar-
68 macological or genetic blockade of the noradrenaline
69 transporter protected nigrostriatal dopaminergic neurons
70 fromMPTP toxicity inmice (Rommelfanger et al. 2004). But
71 how this protective effect is mediated remains unknown.
72 One possibility is that the noradrenergic input from the
73 LC influences glial-mediated changes in the SN and
74 reduces processes such as oxidative and nitrative stress that
75 are associated with the progression of dopaminergic cell
76 death in PD. Indeed, noradrenaline binds to a- and
77 b-adrenoceptors located on astrocytes and glia to regulate
78 the expression of the inflammatory factors, tumour necrosis
79 factor-a and interleukin-1b (Feinstein et al. 2002; Heneka
80 et al. 2003; Heneka and Landreth 2007; Pugh et al. 2007)
81 and alters the expression of inducible NO synthase (iNOS)
82 and NO production (Chang and Liu 2000). In addition,
83 noradrenaline can protect dopaminergic neurons against
84 glial-induced oxidative stress (Troadec et al. 2001).
85 Lipopolysaccharide (LPS) is used to induce activation of
86 microglial cells and astrocytes and the loss of dopaminer-
87 gic neurons in the SN (Castano et al. 1998; Herrera et al.
88 2000, Iravani et al. 2002, 2005, 2008). So, we now inves-
89 tigate the possibility that a prior LC lesion will influence its
90 action. We have compared the effects of direct supra-nigral
91 administration of LPS alone to induce inflammation and
92 nigral cell loss and the effects observed in combination
93 with DSP-4 mediated destruction of the LC.
94 Experimental procedures
95 Experimental animals
96 All animal experiments were conducted according to
97 guidelines set out in the UK Animals (Scientific Proce-
98 dures) Act 1986 and were approved by a local ethical
99 committee at King’s College London. All animals had
100 unrestricted access to food and water and were kept at a
101 12-h light: 12-h dark cycle. In two groups of male Wistar
102 rats (250–300 g), either a single normal saline (1 ml/kg,
103 i.p., n = 10) or a single dose of N-(2-chloroethyl)-N-ethyl-
104 2-bromobenzylamine [dissolved in sterile water as the
105 quantity of DSP-4 used was not fully soluble in 0.9 %
106 saline (DSP-4; 50 mg/kg i.p., n = 14; Sigma-Aldrich,
107 Poole, UK)] was administered. A single 50 mg/kg i.p. dose
108 of DSP-4 leads to profound loss of noradrenaline (80 and
109 50 % loss in the cortex and the substantia nigra, respec-
110 tively) within 3 days (Fornai et al. 1997).
111 Stereotaxic surgery
112 One week following administration of saline or DSP-4, on
113 day eight, animals were anaesthetised with a mixture of
114isoflurane (3–5 % for induction, 1–1.5 % for maintenance)
115and 95 % O2, 5 % CO2. While maintained under isoflurane
116anaesthesia, rats were placed in a Kopf stereotaxic frame
117(Tijunga, USA) with the incisor bar set at -3.3 mm. Body
118temperature was measured using a rectal probe and main-
119tained at 37 ± 1 C using a thermostatic heating blanket
120underlying the animal.
121The saline-treated animals were supra-nigrally admin-
122istered with 2 ll filter-sterile 0.1 M phosphate-buffered
123saline (PBS, pH 7.4; n = 4) or LPS (Calbiochem, c/o
124Merck, Darmstadt, Germany, serotype 055:B5, E. coli;
125n = 8) dissolved at a concentration of 2 lg/ll in a volume
126of 2 ll (total dose, 4 lg). The DSP-4 treated animals were
127also treated supra-nigrally with 4 lg LPS (n = 8). The
128following stereotaxic co-ordinates were used: AP,
129-4.8 mm; L, 2.0 mm; V, -7.6 mm. This location corre-
130sponded to the largest segment of SN in the coronal plane
131(Paxinos and Watson 1986). All nigral administrations
132were carried out using a 5-ll Hamilton syringe for a period
133of 2 min using a Kopf series 5000 microinjector in accord
134with a previously used protocol (Iravani et al. 2008). The
135remaining DSP-4 treated rats were used as DSP-4 controls.
136Immunohistochemistry
137Tyrosine hydroxylase (TH) immunoreactivity was assessed
138in the LC and SN as a marker of noradrenergic and
139dopaminergic neurons, respectively. GFAP and OX-6 and
140OX-42 immunoreactivity were used as markers of astrocyte
141and microglial activation. Expression of iNOS and 3-ni-
142trotyrosine (3-NT), immunoreactivity was used to assess
143nitrative stress in the SN. P47phox immunoreactivity was
144used as a marker of NADPH-oxidase activation and
145superoxide formation.
146At 24 h following supra-nigral PBS or LPS administra-
147tion, animals were euthanised by CO2 exposure until
148breathing completely stopped. The thoracic cavity was
149quickly opened; animals were intra-cardially perfused with
1500.1 M PBS, pH 7.4 at 4 C followed by phosphate-buffered
1514 % paraformaldehyde solution. Directly after perfusion,
152the brains were removed, post fixed for a further 48 h,
153washed in 0.1 M PBS, and cryoprotected in 30 % sucrose
154solution for 4–6 days. Coronal sections from the blocks
155containing the locus coeruleus and the substantia nigra were
156cut at 30 lm using a Leica freezing microtome and these
157were kept free-floating in 0.1 M PBS containing 0.01 %
158sodium azide until processed for immunohistochemistry.
159Sections were either processed for avidin–biotin peroxi-
160dase complex immunohistochemistry using the appropriate
161rabbit or mouse ABC Vectastain kit (Vector Laboratories) in
162which case immunoreactivity was observed using 3,3-diam-
163inobenzidine (DAB, Sigma) as the chromagen. For immu-
164nohistochemical studies, the polyclonal anti-TH (Pel-freeze,
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165 Rogers, USA; 1:500), the anti-iNOS (Calbiochem, Germany;
166 1:1,000), anti-3-NT (Upstate Laboratories, Lake Placid, NY,
167 USA; 1:1,000), anti-GFAP (Promega; 1:200), and p47phox
168 (SantaCruzBiotechnology, Inc., CA,USA1:200)were raised
169 in rabbit. Microglia were detected using monoclonal anti-
170 bodies detecting anti-CD11b (clone, OX-42; 1:50) andMHC-
171 II (clone, OX-6; 1:50) (Serotec, Kidlington, Oxon, UK). For
172 the purpose of double-labelled immunofluorescence, mono-
173 clonal antibody raised against the astrocytic marker GFAP
174 (Chemicon) was also used in combination with polyclonal
175 glial cell line-derived neurotrophic factor (GDNF, Santa Cruz
176 Biotechnology, Inc., CA, USA 1:500) antibody. TH colocal-
177 isation with COX-2 (Transduction Laboratories; 1:200) was
178 assessed using polyclonal and monoclonal antibodies,
179 respectively. To determine the possible colocalisation of
180 p47phox with microglia, dopaminergic neurons or astrocytes,
181 double immunofluorescencewas performedonnigral sections
182 using a combination of cyclooxygenase-2 (COX-2) and
183 p47phox, with TH or GFAP with GDNF, respective mono-
184 clonal or polyclonal primary antibodies were used. The sec-
185 ondary antibodies were tagged with either fluorescein
186 isothiocyanate (FITC) or Texas Red as fluorophores.
187 Cell counting
188 The number of tyrosine hydroxylase-immunoreactive
189 (TH-ir) neurons at the level of the third nerve was derived
190 from manually counting the total TH-ir neurons from 3 to 7
191 adjacent sections using two independent observers. Based
192 on the counting of dopaminergic neurons throughout the
193 SN at regular 100-lm intervals, we previously showed that
194 the third nerve rootlets provide a reliable anatomical
195 landmark at which the extent of cell loss can be accurately
196 assessed and that the extent of cell loss at this point is
197 reflective of cell loss throughout the entire structure (Ira-
198 vani et al. 2002, 2005; Bukhatwa et al. 2009). The counts
199 obtained correlate precisely with unbiased stereology using
200 the dissector method (see Buthatwa et al. 2009). The extent
201 of dopamine neuronal loss was estimated by counting the
202 number of TH-ir SN neurons at the level of the third nerve
203 rootlets on the lesioned side compared with the control side
204 of the SN. For counting microglial cells, using the 209
205 objective, a grid with a field of 500 9 500 lm (area:
206 0.25 mm
2) was placed randomly at different regions within
207 the SN. Sections were visualised using a Zeiss Axioskop II
208 microscope equipped with an Axiocam digital camera.
209 Data analysis
210 The data for manual TH-ir cell counts in the LC and the
211 SN from each treatment group were expressed as
212 mean ± standard error of mean (SEM). Mean of cell
213 counts ± SEM was compared using Student’s t test using
214Prism 4.0 software (GraphPad, San Diego, CA USA).
215Where multiple groups of data were compared, as in the
216case of comparison of nigral cell counts following different
217treatments, a one-way ANOVA followed by Neuman–
218Keul’s multiple comparison post hoc test was used.
219Results
220DSP-4 treatment effects on TH-ir in LC
221In the LC where TH-immunoreactivity (-ir) reflects norad-
222renergic neurons, examination of ABC-immunoperoxidase
223or FITC-immunofluorescence in sections from saline-treated
224control rats revealed numerous large spherical TH-ir neurons
225(Fig. 1a, c, e, g). One week following administration of a
226single 50 mg/kg dose of DSP-4, there was a marked
227degeneration of these neurons by approximately 60 %
228compared to saline-treated control in rats (Fig. 1b, d, f, h).
229Effects of DSP-4 treatment on TH-ir in SN
230In the substantia nigra (SN), where TH-ir labelling reflects
231dopaminergic neurons, numerous strongly stained TH-ir
232neurons were observed in the saline control sections while
233DSP-4 treated rats exhibited somewhat paler staining.
234However, no difference between the saline control and the
235DSP-4 treated rats was found in the number or morphology
236of TH-ir neurons. When the total number of nigral TH-ir
237(DAergic) neurons/hemisphere at the level of 3rd nerve was
238counted following nigral vehicle (PBS) administration, no
239significant difference could be detected between the number
240of TH-ir neurons in the SN of rats treated with saline (i.p.)
241plus nigral PBS or DSP-4 (saline: 129 ± 17, n = 4 vs.
242DSP-4: 148 ± 14 n = 6; p[ 0.05). The TH-ir neuronal
243counts in this group were not significantly different from the
244neuronal counts of the contralateral SN of either the LPS
245plus saline or LPS plus DSP-4 treated animals (Fig. 2).
246Following supra-nigral LPS (4 lg) administration in
247saline (i.p.) pre-treated rats, an approximately 50 % loss of
248ipsilateral TH-ir neurons occurred compared to the con-
249tralateral SN (Fig. 2). In rats pre-treated with DSP-4
250(50 mg/kg), loss of TH-ir neurons following supra-nigral
251LPS was not significantly different (Fig. 2c, d, e).
252LPS induced microgliosis in control or DSP-4 treated
253rat SN
254In the contralateralSNofDSP-4plusLPS, or in rats pre-treated
255with DSP-4 alone, a modest 3-NT expression was frequently
256observed within small cellular entities resembling microglia
257(Fig. 3A). In rats pre-treated systemically with saline, 4 lg
258LPS led to marked expression of 3-NT-ir (Fig. 3Bb, d) and
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259 iNOS-ir (Fig. 3Cb, e), while the contralateral SN in saline pre-
260 treated rats was devoid of 3-NT-ir (Fig. 3Ba) or iNOS-ir
261 (Fig. 3Ca, d). In rats pre-treated with DSP-4, LPS adminis-
262 tration resulted in markedly reduced expression of both 3-NT
263 (Fig. 3Bc, e) and iNOS-ir (Fig. 3Cc, f).
264 In the untreated SN, the OX-42 positive microglia
265 remained ‘‘ramified’’ and uniformly distributed throughout
266 this structure in an ‘‘un-activated’’ state. Rarely, a few OX-
267 42-ir was observed following supranigral administration of
268 saline (Fig. 4Aa). Following DSP-4 alone, there was evi-
269 dence of partial activation of microglia (Fig. 4Ab, see fine
270 arrows). Following LPS administration in saline-pretreated
271 rats, OX-42-ir cells became fully activated as evidenced by
272 the thickening of processes and acquisition of amoeboid
273 morphology (Fig. 4Ac). When the LPS-treated SN was
274 assessed for OX-6-ir, a marked increase in the number of
275 OX-6-ir expressing stellate morphology (Fig. 4Ba, b) was
276 observed. In rats pre-treated with DSP-4, the number of
277 OX-6?ve activated microglia was markedly reduced
278 (Fig. 4C). Furthermore, following DSP-4 treatment, the
279 morphology of the OX-6-ir cells was also altered. These
280 cells lost their stellate characteristic and became more
281 punctate (Fig. 4Bc, d). Overall, there was a significantly
282 smaller number of OX-6-ir cells following DSP-4 pre-
283 treatment (Fig. 4C).
284LPS induced glial and neuronal p47phox expression
285in saline or DSP-4 pre-treated rats
286Following supranigral LPS administration in saline pre-
287treated (i.p.) rats, marked expression of nigral p47phox-ir was
288observed (Fig. 5Aa, Ba). Double-labelled immunofluores-
289cence of p47phox with either OX-42 (Fig. 5Ab) or OX-6
290(Fig. 5Bb) showed a good staining overlap (Fig. 5Ac, Bc,
291see fine arrows). In rats pre-treated with DSP-4, there was a
292poor overlap of OX-42 (Fig. 5Af) and OX-6 (Fig. 5Bf) with
293p47phox-ir. Only rarely didmergingOX-42-ir or OX-6-ir with
294p47phox-ir images show an overlap.
295We assessed the morphology and population of p47phox-ir
296following LPS in the SN of either the saline or the DSP-4
297pre-treated rats. The expression of p47phox-ir in the SN of
298saline pre-treated rats was confined to numerous small
299(\10 lm diameter) cells (Fig. 6a, c), distributed throughout
300the treated SN compacta (SNc) and the SN reticulata
301(Fig. 6a). In the DSP-4 pre-treated rats, most of p47phox-ir
302was confined to larger ([15 lm) cells located in the region
303corresponding to the SNc (Fig. 6b, e). These p47phox-ir cells
304had neuron-like morphology (Fig. 6e). There were also
305numerous small cells in the SNr that were p47phox-ir
306(Fig. 6d) but their population was less dense than those
307observed in rats treated with LPS alone (Fig. 6f, g).
Fig. 1 Marked reduction of TH-ir neurons was observed in the locus
coeruleus following administration of 50 mg/kg (i.p.) DSP-4. In
saline-treated control rats, locus coeruleus contained numerous TH-ir
neurons (a peroxidase -ir, c, e, g fluorescence-ir), but 1 weeks
following a single i.p. administration of DSP-4, the number of TH-ir
neurons was markedly reduced at all rostral (c, d), middle (e, f) and
caudal levels (g, h). The histogram represents mean ± SEM total cell
counts from 5 to 7 rats per group. *p\ 0.05, Student’s unpaired t test
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308 Co-localisation of TH with p47phox and COX-2
309 Double immunofluorescence using TH and p47phox fol-
310 lowing LPS in saline pre-treated rats showed no colocal-
311 isation of TH-ir in small p47phox-ir cells. Only rarely was
312 the colocalisation of TH-ir and p47phox-ir observed in large
313 cells with neuronal morphology following LPS alone
314 (Fig. 7Aa–c, see large arrow). However, in rats pre-treated
315with DSP-4, administration of LPS resulted in nearly all
316TH-ir neurons expressing p47phox-ir (Fig. 7Ad–f).
317Supra-nigral LPS administration led to marked
318expression of COX-2 within the TH-ir neurons but no
319COX-2-ir in the contralateral SN (Fig. 7Ba–c). However,
320following LPS administration in the DSP-4 treated rats,
321virtually no TH and COX-2 co-localisation was seen
322(Fig. 7Bd–f).
Fig. 2 Loss of TH-ir in the SN
following nigral administration
of LPS. In the saline (i.p.) pre-
treated rats, administration of
4 lg LPS led to a marked
reduction of TH-ir neurons in
the SN. Compared to control
(a) and DSP-4 pre-treated rats
(b), supranigral administration
of LPS alone (c) or following
systemic DSP-4 (d) marked loss
of TH-ir occurred. The lower
panel (e) summarises the TH-ir
cells counts following different
treatments. TH-ir cell counts in
the SN of DSP-4 pre-treated rats
and the contralateral SN of other
group did not differ
significantly, but LPS
administration significantly
reduced TH-ir cells in both
saline and DSP-4 pre-treated
groups. *p\ 0.05, one-way
ANOVA followed by Neuman–
Keul’s multiple comparison test
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Fig. 3 The effects of DSP-4 alone A and LPS on 3-nitrotyrosine
(3-NT; B) and inducible nitric oxide synthase (iNOS; C) expression in
saline (Ba, Ca) pre-treated rat SN. In DSP-4 pretreated rats cells with
glial cell morphology (a and b, see arrows) were frequently observed
in the SN (Ba, b). Following supranigral LPS in the saline group,
numerous punctate cellular structures expressing 3-NT-ir (mag: 94;
Ab; mag: 940; Ad) and a marked iNOS expression in amoeboid
cells (Bb, e; mag: 9100 and 920, respectively) were observed.
Administration of LPS following DSP-4 markedly reduced 3-NT (Bc,
94; Be, 940; scale bars 50 lm) and the iNOS-ir cells (Cc, f).
Examination at high optical magnification (mag: 9100; Cb, c)
revealed that these cells had a different morphology. Data for 3-NT
and iNOS-ir punctate cell counts in an area of 25,000 lm2 from LPS
alone or LPS ? DSP-4 treated rats are expressed as mean ± SEM
and shown in the lower panels. *p\ 0.05, unpaired Student’s t test
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Fig. 5 Microglial (OX-42,
A and OX-6, B positive cells)
co-localisation with p47phox
following supranigral LPS in
saline pre-treated (Aa–c;
Ba–c) or LPS following DSP-4
pre-treatment (Ad–f; Bd–f). In
saline pre-treated rats, LPS led
to co-localisation of OX-42 (Ac,
small arrows) or OX-6-ir (Bc,
small arrow) with p47phox-ir.
Following LPS administration
in DSP-4 pre-treatment rats,
there was no colocalisation of
p47phox with OX-42 (Af) and
OX-6 (Bf)
Fig. 4 The effect of LPS, DSP-4 and DSP-4 plus LPS on microglial
expression in SN. OX-42-ir in saline-treated rats showed the presence
of numerous ‘‘resting’’ microglia (Aa), but in DSP-4 treated rats,
several partially activated OX-42 positive microglia were evident
(small arrows; Ab). Following supranigral LPS administration,
microglia entered an activated state, and several amoeboid cellular
structures were visible (Ac; large arrows). Administration of LPS
following DSP-4 pre-treatment resulted in fewer amoeboid OX-42-ir
cells (Ad). Following LPS alone, numerous OX-6 positive cells were
observed in the SN (Ba). These cells had prominent stellate
characteristics (Bb). LPS administration following DSP-4 led to
appearance of punctate OX-6 positive cells (Bd). Since unlike OX-42
there was little or no OX-6 immunoreactivity under resting condition,
for ease and accuracy of the cell counts only the number of OX-6?ve
cells was recorded. Panel (C) shows the mean ± SEM number of
OX-6 cells exhibiting stellate morphology (n = 8). LPS led to a
marked and a highly significant increase in the number of stellate OX-
6 positive cells in vehicle or DSP-4 treated rats (p\ 0.001; one-way
ANOVA), but compared to LPS alone there was a marked and
significant reduction (p\ 0.001; one-way ANOVA; followed by
Neuman–Keul’s multiple comparison test) in the increase of stellate
OX-6 cell counts in rats that were pre-treated with DSP-4
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323 Effect of DSP-4 treatment on astrocytosis
324 In the SN of the control, saline (i.p.) pre-treated rats, only a
325 few GFAP-ir astrocytes were seen. These GFAP-ir cells
326 had a relatively faint staining, with a fine fibrillar structures
327 and a very small central core. Administration of LPS sig-
328 nificantly up-regulated GFAP-ir in the ipsilateral SN,
329 compared to the contralateral SN or the SN of saline pre-
330 treated control animals. Following LPS alone, the number
331 of GFAP-ir astrocytes increased by more than 100 %
332 (138 ± 18 vs. 267 ± 27; p\ 0.05; Fig. 8). Eight days
333 following DSP-4 (i.p.) alone, a marked proliferation of
334 GFAP-ir cells took place in the SN in both hemispheres
335 equally, such that the number of these cells was even
336 greater than those seen following LPS in the saline pre-
337 treated rats. Furthermore, in addition to a significant
338 increase in number, the GFAP-ir cells had broader fibrillar
339 morphology, though appeared to be shorter in length, but
340 their central cores were greatly enlarged-nuclear hyper-
341 trophy. In rats pre-treated with DSP-4, supranigral
342 administration of LPS did not lead to a further increase in
343 the number or further hypertrophy of the GFAP-ir. There
344was an increase in number of GFAP-ir in the ipsilateral
345SN compared to the contralateral SN (ipsilateral SN:
346338 ± 23; contralateral SN: 314 ± 17), but the difference
347was not statistically significant (see Fig. 8).
348Localisation of glial cell line-derived neurotrophic
349factor (GDNF) in astrocytes and the effect of DSP-4
350pre-treatment
351Following LPS administration in saline (i.p.) pre-treated
352rats, up-regulation of numerous GDNF-ir was observed
353within GFAP ?ve astrocytes (Fig. 9a–f). In the control SN
354administered with PBS, GFAP-ir was only faintly expres-
355sed and only few GFAP ?ve astrocytes were also GDNF
356positive. In rats pre-treated with systemic DSP-4 8 days
357earlier, LPS administration led to a general absence of co-
358localisation of GDNF within GFAP-ir astrocytes, although
359GFAP-ir was robustly up-regulated (Fig. 9g–i). In DSP-4
360treated rats, astrocytes displayed marked hypertrophy
361exhibiting more rounded central morphology with fewer
362ramifications, though fibrillar diameters appeared to be
363broader.
Fig. 6 In saline pre-treated rats,
LPS administration led to a
prominent SNc/SNr expression
of p47phox-ir in cells with
predominantly punctate
microglial morphology (a, c,
broad arrows). In the SN of rats
treated with LPS following
DSP-4 pre-treatment, fewer
punctate cells were p47phox-ir
(b, d) in the SNr but there was
extensive neuronal expression
of p47phox in the SNc region
(b, e, cell within the fine
arrows). Panels f and g show
mean ± SEM nigral p47phox-ir
cell counts. There were a
significantly greater number of
cells with glial morphology that
were counted following LPS
alone (f). Expression of
p47phox-ir cells with neuronal
morphology was significantly
greater following DSP-4 alone
or DSP-4 plus LPS (g).
*p\ 0.05; **p\ 0.001, One-
way ANOVA, followed by
Neuman–Keul’s multiple
comparison test
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364 Discussion
365 Noradrenergic innervation of the SN is purported to
366 influence the survival of dopaminergic neurons in PD but
367 the underlying mechanisms are not known. This study
368 suggests that a modulation of glial-induced inflammatory
369 response may be at least partially responsible. As previ-
370 ously reported in rodents treated with the NAergic toxin,
371 DSP-4 (Dudley et al. 1990; Fritschy and Grzanna 1991),
372 the present study shows that an approximately 60 % loss of
373 TH-positive neurons occurred in the LC while the number
374 of TH-positive cells in substantia nigra was unaffected. We
375 then used a submaximal concentration of LPS [4 lg
376 compared to 10 lg LPS used in earlier studies (Castano
377 et al. 1998; Iravani et al. 2002; Arimoto and Bing 2003)] to
378 induce inflammatory damage in SN. This protocol was
379adopted to allow a potential exacerbation of LPS SN cell
380loss by prior DSP-4 treatment that was to be observed. As
381expected, (Castano et al. 1998; Herrera et al. 2000; Iravani
382et al. 2002) injection of a submaximal dose of LPS induced
383nigral TH-positive cell loss. However, and unexpectedly,
384there was no further loss of TH-positive cells in SN
385induced by LPS when used in animals with a prior DSP-4
386induced lesion of LC. This is at odds with the previous
387literature on the effects of DSP-4 lesioning of LC on MPTP
388or 6-OHDA induced nigral dopaminergic cell loss (Nishi
389et al. 1991; Marien et al. 1993; Bing et al. 1994; Fornai
390et al. 1996, 1997; Srinivasan and Schmidt 2003). However,
391this is the first study to induce dopaminergic cell death
392indirectly through an inflammatory mechanism using LPS
393following NA depletion and so a similar exacerbation of
394neuronal destruction seems not to occur. However, changes
Fig. 7 A Co-localisation of
TH-ir with p47phox within SN
(Aa–c). Following saline (i.p)
pre-treatment, LPS
administration led to few
surviving TH-ir neurons
expressing p47phox-ir (top
panel, large arrows) but
numerous small cells with
microglial morphology
expressed p47phox-ir (Ab,
small arrows). However, in
DSP-4 pre-treated rats, LPS
administration led to nearly all
surviving TH-ir neurons (Ad) to
express p47phox-ir (Ae, f).
B Following saline pre-
treatment, TH-(Ba) and COX-2-
ir (Bb) were colocalised in
surviving dopaminergic neurons
following LPS administration
(Ba–c). Following DSP-4 pre-
treatment, administration of
LPS led to COX-2-ir to be
poorly co-localised with TH-ir.
Arrow-heads TH-ir neurons,
small arrows COX-2-ir neurons
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395 in the inflammatory response to LPS in SN were seen as
396 predicted by our original hypothesis.
397 LPS administration into SN induced both astrocytosis
398 and microgliosis in confirmation of our previous studies
399(Iravani et al. 2002, 2005, 2008). The LPS-induced astro-
400cytosis was accompanied by an up-regulation of GDNF as
401shown by co-localisation with GFAP immunoreactivity
402(Iravani et al. 2012). However, surprisingly DSP-4
Fig. 8 GFAP immunoreactivity in saline (a) DSP-4 alone (b) LPS (c)
and LPS in DSP-4 pre-treated nigra (d). Compared to the control SN
administered with PBS (a) where little GFAP-ir astrocytosis was
observed, LPS administration resulted in marked activation of GFAP-
ir (b). In rats pre-treated with DSP-4 alone (c), a much greater level of
GFAP-ir was observed bilaterally compared to saline pre-treated rats
and supranigral LPS where the increase in GFAP-ir was observed
only in the ipsilateral SN. In rats pre-treated with DSP-4 and
supranigral LPS administration, expression of GFAP-ir was not
further enhanced (d). Panel e compares the number of GFAP-ir cells
in a grid area of 25,000 lm2 in the ipsilateral and the contralateral
SN. GFAP-ir cells were counted and expressed as mean ± SEM
(n = 8). Note that in all conditions, DSP-4 was administered as pre-
treatment; the number of GFAP-ir in the contralateral SN was
similarly increased compared to the ipsilateral SN. *p\ 0.05;
***p\ 0.0001; one-way ANOVA, followed by Neuman–Keul’s
multiple comparison test
Fig. 9 Nigral colocalisation of
GFAP and GDNF following
LPS in saline pre-treated
(a–f) and DSP-4 pre-treated
(g–i) rats. Supranigral
administration of 4 lg LPS
results in marked astrocytosis
(a, d) and expression of GDNF
(b) in saline pre-treated rats. At
high magnification (9100), a
prominent expression of GDNF
within GFAP ?ve astrocytes is
observed (f). In rats pre-treated
with DSP-4, supranigral
administration of LPS resulted
in marked astrocytosis (g), but
little GDNF expression within
GFAP ?ve astrocytes was
evident (h, i)
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403 treatment alone also led to a marked astrocytosis in the SN
404 which was greater than that observed for LPS alone, even
405 though no SN neuronal loss occurred, but there was no up-
406 regulation of GDNF. Following DSP-4 treatment alone or
407 DSP-4 combined with LPS treatment, there was little evi-
408 dence of GFAP and GDNF co-localisation despite the
409 extensive astrocyte proliferation. These observations sug-
410 gest that the NAergic input from LC is essential for the
411 normal functioning of astrocytes and trophic factor pro-
412 duction and that the phenotype of reactive astrocytosis
413 depends strongly on the nature injury-inducing stimulus
414 (see Zamanian et al. 2012).
415 Loss of LC noradrenergic input to substantia nigra also
416 had a marked effect on the response of microglia to LPS
417 administration. In the normal SN, microglia with ramified
418 morphology are abundantly expressed as identified by OX-
419 42 immunoreactivity with a few MHC-II macrophagic cells
420 with stellate or rounded morphology that are OX-6
421 immunoreactive. This is consistent with the presence of
422 abundant resting microglia. Following LPS treatment, OX-
423 42 positive cells in SN lost their ramifications, became
424 enlarged and had amoeboid morphology, and numerous
425 OX-6 positive cells with predominantly stellate morphol-
426 ogy were present. DSP-4 treatment alone induced a short-
427 ening and broadening of OX-42 positive cell branching
428 indicative of partial microglial activation. This suggested
429 that depletion of NA could initiate modest microglial
430 activation in addition to the effects seen on astrocytic
431 function. However, following DSP-4 pre-treatment, LPS
432 administration resulted in a smaller increase in both OX-42
433 and OX-6 immunoreactivity compared to that seen with
434 LPS alone suggesting a controlling influence of LC input
435 on the inflammatory response to LPS.
436 To determine the functional importance of the inflam-
437 matory response induced by loss of LC input, we assessed
438 markers of both oxidative and nitrative stress associated
439 with gliosis. NO derived from iNOS is an important con-
440 tributor to LPS-induced nigral dopaminergic cell loss as it
441 becomes highly toxic when combined with superoxide to
442 form peroxynitrite that then reacts with tyrosine residues to
443 form 3-NT (Iravani et al. 2006). We, therefore, looked at the
444 effect of NA depletion on both iNOS expression and 3-NT
445 formation. LPS alone induced a marked increase in iNOS
446 expression that co-localised with OX-42- and OX-6
447 immunoreactive cells and induced immunoreactivity for
448 3-NT (Iravani et al. 2005). Following combined DSP-4 and
449 LPS treatment, the number of iNOS expressing cells and the
450 intensity of 3-NT immunoreactivity were reduced in line
451 with the observation of reduced microglial number. To
452 assess alterations in oxygen radical formation, p47phox was
453 used as a marker of up-regulated NADPH-oxidase activity
454 (Lavigne et al. 2001; Iravani et al. 2005). Following nigral
455 LPS administration, p47phox was up-regulated and co-
456localised with both OX-42 and OX-6 immunoreactive cells.
457This implies that activated microglia produce both NO and
458O2
- to form peroxynitrite. However, following combined
459DSP-4 and LPS treatment, the number of glial cells in SN
460expressing p47phox was markedly reduced. In contrast, the
461majority of p47phox immunoreactivity was now present in
462TH-positive neurons. This suggests that in the absence of
463NA, dopaminergic neurons become directly involved in the
464generation of oxidative stress. Finally, we assessed super-
465oxide formation in dopaminergic neurons using COX-2
466immunoreactivity. In the normal SN, COX-2 immunore-
467activity is not present in either neurons or in glia. However,
468as previously reported, following LPS treatment, there was
469prominent expression of COX-2 in TH immunoreactive
470neurons (O’Banion 1999; Teismann et al. 2003; de Meira
471Santos Lima et al. 2006). However, following combined
472DSP-4 and LPS treatment, COX-2 immunoreactivity was
473not co-localised with TH-positive cells. Recently, Schla-
474chetzki et al. (2010) have shown that combination of nor-
475adrenaline and LPS in cortical primary microglial culture
476enhanced COX-2 expression. In the present study, LPS
477following NA depletion by DSP-4 resulted in downregula-
478tion of COX-2 suggesting an important role for NA in the
479regulation of inflammatory processing and the role of COX-
4802, which is implicated therein. Consequently, it is possible
481that loss of LC input to SN removes the NA-mediated
482neuronal COX-2 response to inflammatory event. It also
483suggests that loss of LC input to SN removes the response of
484neuronal COX-2 to inflammatory events.
485In conclusion, LPS-induced nigral dopaminergic cell
486loss is not exacerbated by the loss of LC noradrenergic
487input in the same way that occurs with directly acting
488neuronal toxins such as MPTP and 6-OHDA. Rather, there
489is a complex effect on glial cell activation and markers of
490inflammatory change. A reduction in glial markers of ni-
491trative and oxidative stress following loss of LC input
492suggests that LPS-induced nigral cell death should be
493reduced but this might be balanced by the decrease in
494trophic factor production that also ensues. The complex
495sequence of events that occurs in the regulation of
496inflammatory events in SN following loss of LC input may
497have relevance to early neuronal loss in PD. A change in
498the ability of glial cells to ‘protect’ nigral dopaminergic
499neurons from toxic events may affect their survival and the
500extent of LC loss may then partially determine the rate of
501disease progression.
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